Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 477

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 477
---
 of sales of the IPO. On November 30, 2022, the Sponsor entered into a Sponsor Forfeiture Agreement (the “Sponsor Forfeiture Agreement”) with the Company and Liminatus, pursuant to which, contingent upon Closing, the Sponsor agreed to forfeit all 4,177,778 of its Private Placement Warrants to purchase shares of the Company’s Class A common stock, exercisable at $11.50 per share (the “Forfeited Private Placement Warrants”), acquired by the Sponsor in March 2021 in connection with the Initial Public Offering. At the Closing, the Forfeited Private Placement Warrants shall be transferred from the Sponsor to the Company for cancellation in exchange for no consideration and the Company shall retire and cancel all of the Forfeited Private Placement Warrants. NOTE 5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES As of December 31, 2023 and 2022, the accounts payable and accrued liabilities of the Company consisted of the following:

| ​                        | ​ | ​ | December 31,2023 |   |           |   | ​ | ​ | December 31,2022 |   |           |   | ​ |
|:-------------------------|:--|:--|:-----------------|:--|----------:|:--|:--|:--|:-----------------|:--|----------:|:--|:--|
| Accounts payable         | ​ | ​ | ​                | $ | 1,996,912 | ​ | ​ | ​ | ​                | $ |   594,958 | ​ | ​ |
| Accrued legal expense    | ​ | ​ | ​                | ​ |    45,400 | ​ | ​ | ​ | ​                | ​ |   826,134 | ​ | ​ |
| Accrued expenses – other | ​ | ​ | ​                | ​ |   284,606 | ​ | ​ | ​ | ​                | ​ |    68,370 | ​ | ​ |
| ​                        | ​ | ​ | ​                | $ | 2,326,918 | ​ | ​ | ​ | ​                | $ | 1,489,462 | ​ | ​ |

F-44

TABLE OF CONTENTS

### IRIS ACQUISITION CORP

### NOTES TO FINANCIAL STATEMENTS

#### NOTE 6.   RELATED PARTY TRANSACTIONS

#### Founder